A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

NCT06234605 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: HC-7366
DRUG: Belzutifan

Sponsor

HiberCell, Inc.

Collaborators

[object Object]